List of Viramune Xr drug patents

Viramune Xr is owned by Boehringer Ingelheim.

Viramune Xr contains Nevirapine.

Viramune Xr has a total of 1 drug patent out of which 0 drug patents have expired.

Viramune Xr was authorised for market use on 25 March, 2011.

Viramune Xr is available in tablet, extended release;oral dosage forms.

Viramune Xr can be used as treatment of hiv-1 by once daily administration.

The generics of Viramune Xr are possible to be released after 12 March, 2029.

VIRAMUNE XR's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8460704 BOEHRINGER INGELHEIM Extended release formulation of nevirapine
Mar, 2029

(5 years from now)

Drugs and Companies using NEVIRAPINE ingredient

Market Authorisation Date: 25 March, 2011

Treatment: Treatment of hiv-1 by once daily administration

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of VIRAMUNE XR before it's patent expiration?
More Information on Dosage

VIRAMUNE XR family patents

3

United States

2

Peru

1

Uruguay

1

Spain

1

Brazil

1

Colombia

1

New Zealand

1

Mexico

1

Argentina

1

Morocco

1

China

1

Taiwan, Province of China

1

Korea, Republic of

1

Hong Kong

1

EA

1

Tunisia

1

South Africa

1

Canada

1

Japan

1

Hungary

1

Ukraine

1

Poland

1

Chile

1

Australia

1

Ecuador

1

Denmark

1

European Union

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in